NYSE: NUSNu Skin Enterprises Inc Stock
$12.70+0.34 (+2.75%)
Updated Apr 18, 2024
NUS Price
$12.70
Fair Value Price
N/A
Market Cap
$627.65M
52 Week Low
$11.84
52 Week High
$41.50
P/E
74.71x
P/B
0.76x
P/S
0.49x
PEG
0.04x
Dividend Yield
9.69%
Revenue
$1.97B
Earnings
$8.60M
Gross Margin
68.9%
Operating Margin
1.35%
Profit Margin
0.4%
Debt to Equity
1.2
Operating Cash Flow
$119M
Beta
0.78
Next Earnings
May 8, 2024
Ex-Dividend
N/A
Next Dividend
N/A
NUS Overview
Nu Skin Enterprises, Inc. distributes beauty and wellness products in the U.S. and internationally. The company's skin care systems ageLOC Spa systems, ageLOC Transformation anti-aging skin care systems, ageLOC LumiSpa skin treatment and cleansing devices, and ageLOC Boost. It also offers other cosmetic and personal care products, LifePak nutritional supplements, ageLOC Meta nutritional supplements, skin care supplements, and weight management products. Nu Skin Enterprises was founded in 1984 and is headquartered in Provo, UT.
Zen Score
–
Industry Average (36)
You've viewed Zen Score for 10/10 free stocks. Upgrade to Premium to see how NUS scored across 38 valuation, financial, forecast, performance, and dividend due diligence checks.
Due Diligence Checks
NUS ($12.70) is trading below its intrinsic value of $101.58, according to an updated version of Benjamin Graham's Formula from Chapter 11 of "The Intelligent Investor"
Below Benjamin Graham Formula Value Valuation
NUS is poor value based on its earnings relative to its share price (74.71x), compared to the US market average (41.33x)
P/E vs Market Valuation
NUS is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
There are 35 more NUS due diligence checks available for Premium users.
Be the first to know about important NUS news, forecast changes, insider trades & much more!
NUS News
Valuation
NUS price to earnings (PE)
For valuing profitable companies with steady earnings
Company
74.71x
Industry
34.94x
Market
41.33x
NUS is poor value based... subscribe to Premium to read more.
P/E vs Industry Valuation
NUS is poor value based... subscribe to Premium to read more.
P/E vs Market Valuation
NUS price to book (PB)
For valuing companies that are loss-making or have lots of physical asset
Company
0.76x
Industry
7.21x
NUS is good value based... subscribe to Premium to read more.
P/B vs Industry Valuation
NUS price to earnings growth (PEG)
For valuing profitable companies with growth potential
NUS is good value based... subscribe to Premium to read more.
PEG Value Valuation
NUS's financial health
Profit margin
Revenue
$488.6M
Net Income
$7.3M
Profit Margin
1.5%
NUS's Earnings (EBIT) of $26.58M... subscribe to Premium to read more.
Interest Coverage Financials
NUS's profit margin has decreased... subscribe to Premium to read more.
Profit Margin Growth Financials
Assets to liabilities
Assets
$1.8B
Liabilities
$984.5M
Debt to equity
1.2
NUS's short-term assets ($701.87M) exceed... subscribe to Premium to read more.
Short-term Liabilities Financials
NUS's short-term assets ($701.87M) exceed... subscribe to Premium to read more.
Long-term Liabilities Financials
NUS's debt has increased relative... subscribe to Premium to read more.
Shrinking Debt Financials
NUS's debt to equity ratio... subscribe to Premium to read more.
Healthy Debt to Equity Financials
Cash flow
Operating
$54.2M
Investing
-$15.4M
Financing
-$20.3M
NUS's operating cash flow ($118.64M)... subscribe to Premium to read more.
Debt Coverage Financials
NUS vs Household & Personal Product Stocks
Nu Skin Enterprises Stock FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.